FY2027 EPS Forecast for AC Immune Increased by Analyst

Key Points

• Leerink Partners has increased its FY2027 earnings per share (EPS) estimate for AC Immune from $0.13 to $0.15, while the current consensus estimate for the company's full-year earnings is at ($0.62) per share.
• AC Immune recently reported quarterly earnings of ($0.25) EPS, falling short of analysts' expectations of ($0.20) EPS, along with a revenue of $1.65 million, below the anticipated $1.98 million.
• Hedge funds currently own 51.36% of AC Immune's stock, with significant investments made by firms such as Northern Trust Corp and Renaissance Technologies LLC in the last quarter.

AC Immune (NASDAQ:ACIU - Free Report) - Leerink Partnrs raised their FY2027 earnings per share estimates for AC Immune in a report released on Tuesday, August 5th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $0.15 per share for the year, up from their prior estimate of $0.13. The consensus estimate for AC Immune's current full-year earnings is ($0.62) per share.

AC Immune (NASDAQ:ACIU - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.05). The company had revenue of $1.65 million for the quarter, compared to analysts' expectations of $1.98 million. AC Immune had a negative net margin of 174.94% and a negative return on equity of 49.35%.

A number of other brokerages have also recently issued reports on ACIU. Wall Street Zen upgraded AC Immune from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th. HC Wainwright lowered their price objective on AC Immune from $16.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, May 1st.

AC Immune Trading Up 2.9%

NASDAQ:ACIU traded up $0.06 during trading hours on Thursday, reaching $2.14. 97,918 shares of the company traded hands, compared to its average volume of 163,494. The business's 50-day moving average price is $2.07 and its two-hundred day moving average price is $2.06. The stock has a market capitalization of $214.88 million, a P/E ratio of -3.69 and a beta of 1.65. AC Immune has a 1 year low of $1.43 and a 1 year high of $3.98.

Institutional Trading of AC Immune

A number of institutional investors and hedge funds have recently modified their holdings of ACIU. Geode Capital Management LLC grew its holdings in shares of AC Immune by 9.9% in the fourth quarter. Geode Capital Management LLC now owns 64,090 shares of the company's stock worth $173,000 after acquiring an additional 5,794 shares during the period. Quinn Opportunity Partners LLC bought a new stake in shares of AC Immune in the fourth quarter worth $27,000. Two Sigma Advisers LP bought a new stake in shares of AC Immune in the fourth quarter worth $36,000. Boothbay Fund Management LLC bought a new stake in shares of AC Immune in the fourth quarter worth $38,000. Finally, Jane Street Group LLC bought a new stake in shares of AC Immune in the fourth quarter worth $66,000. Institutional investors own 51.36% of the company's stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.